Supernus Announces First Quarter 2017 Financial Results
- Net product sales were
$56.4 million , a 31% increase over 2016. - Operating income was
$16.8 million , a 161% increase over 2016. - Diluted earnings per share were
$0.19 , increasing by 138% over 2016. - Early prescription data for Trokendi XR show a strong upward trend following launch in migraine prophylaxis in adults and adolescents.
Commercial Update
First quarter 2017 product prescriptions for Trokendi XR® and Oxtellar XR®, as reported by IMS, totaled 134,855, a 17.1% increase over the first quarter of 2016.
| Prescriptions | |||||||
| Q1 2017 | Q1 2016 | Change % | |||||
| Trokendi XR | 101,695 | 86,227 | 17.9 | % | |||
| Oxtellar XR | 33,160 | 28,913 | 14.7 | % | |||
| Total | 134,855 | 115,140 | 17.1 | % | |||
| Source: IMS | |||||||
Net product sales for the first quarter of 2017 were
| Net Product Sales ($mil.) | |||||||||
| Q1 2017 | Q1 2016 | Change % | |||||||
| Trokendi XR | 30.0 | % | |||||||
| Oxtellar XR | 34.6 | % | |||||||
| Total | 31.2 | % | |||||||
Consistent with historical patterns, product prescriptions and net product sales for the first quarter of 2017 for Trokendi XR and Oxtellar XR were impacted by the continued shift of patients to high deductible and high co-pay plans. Lower wholesaler and pharmacy inventory levels during the first quarter of 2017, compared to the fourth quarter of 2016, had the effect of reducing net product sales by approximately
Trokendi XR Migraine Launch
After receiving final approval from the
While it is still early in the launch, for the first three weeks post launch, IMS prescription data for Trokendi XR show a strong upward trend in total and new prescriptions. During the three week period post launch, total prescriptions were 26,472 compared to 24,109 in the three weeks prior to launch, representing a 10% increase. Similarly, for the same three week period post launch, new prescriptions were 12,978 compared to 10,898 in the three weeks prior to launch, representing a 19% increase. Consistent with these early data, feedback from our sales force indicates that physicians are very receptive to the new indication and appreciate the unique benefits that Trokendi XR brings to migraine patients.
"We are excited about the launch of Trokendi XR in migraine, and are very encouraged by the early IMS prescription data. We continue to believe that the migraine indication should allow us to realize the
full potential of Trokendi XR," said
Progress of Product Pipeline
Enrollment continues in both Phase III trials for SPN-810, currently in development for Impulsive Aggression in patients aged 6 to 12 years who have ADHD. Protocol revisions to improve patient retention during the screening period and programs to drive patient enrollment for the Phase III trials are having a positive impact. We expect enrollment to continue through 2017.
Regarding SPN-812, currently in development for patients aged 6 to 12 years with ADHD, the Company continues to plan to initiate Phase III clinical testing during the second half of 2017. The Company is on track to meet with the
"We look forward to discussing further with the
Operating Expenses
Research and development expenses in the first quarter of 2017 were
Selling, general and administrative expenses in the first quarter of 2017 were
Operating Income and Earnings Per Share
Operating income in the first quarter of 2017 was
Diluted earnings per share for the first quarter of 2017 were
Weighted-average diluted common shares outstanding were approximately 52.8 million in the first quarter of 2017, as compared to approximately 51.2 million in the same period the prior year.
Capital Resources
As of
Financial Guidance
For full year 2017, the Company reiterates its expectation for net product sales, R&D expenses and operating income as set forth below:
- Net product sales in the range of
$265 million to$275 million . - Research and development expense of approximately
$55 million . - Operating income in the range of
$75 million to$80 million . Full year 2017 operating income includes approximately$5 million of non-cash royalty revenue.
Conference Call Details
The Company will hold a conference call hosted by
Please refer to the information below for conference call dial-in information and webcast registration. Callers should dial in approximately 10 minutes prior to the start of the call.
| Conference dial-in: | (877) 288-1043 | ||||||||
| International dial-in: | (970) 315-0267 | ||||||||
| Conference ID: | 9981751 | ||||||||
| Conference Call Name: | Supernus Pharmaceuticals First Quarter 2017 Earnings Conference Call | ||||||||
Following the live call, a replay will be available on the Company's website, www.supernus.com, under ‘Investors'.
About
Forward-Looking Statements:
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information, but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company's ability to sustain and increase its profitability; the Company's
ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company's corporate strategy; the Company's future financial performance and projected expenditures; the Company's ability to increase the number of prescriptions written for each of its products; the Company's ability to increase its net revenue; the Company's ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company's product research and development activities, including the timing and progress of the Company's clinical trials, and projected expenditures; the Company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company's product candidates; the Company's ability to protect its intellectual property and operate its
business without infringing upon the intellectual property rights of others; the Company's expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company's product candidates; the accuracy of the Company's estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company's ability to increase its manufacturing capabilities for its products and product candidates; the Company's projected markets and growth in markets; the Company's product formulations and patient needs and potential funding sources; the Company's staffing needs; and other risk factors set forth from time to time in the Company's
| Consolidated Balance Sheets | ||||||
| (in thousands) | ||||||
| (unaudited) | ||||||
| Cash, cash equivalents and marketable securities | $ | 87,132 | $ | 90,121 | ||
| Accounts receivable, net | 38,885 | 41,527 | ||||
| Inventories, net | 19,167 | 16,801 | ||||
| Prepaid expenses and other current assets | 4,573 | 2,955 | ||||
| Total current assets | 149,757 | 151,404 | ||||
| Long term marketable securities | 89,163 | 75,410 | ||||
| Property and equipment, net | 4,342 | 4,344 | ||||
| Deferred legal fees | 11,331 | 19,860 | ||||
| Intangible assets, net | 29,450 | 16,490 | ||||
| Other non-current assets | 350 | 331 | ||||
| Deferred income tax | 37,863 | 41,729 | ||||
| Total assets | $ | 322,256 | $ | 309,568 | ||
| Accounts payable | $ | 5,056 | $ | 8,055 | ||
| Accrued sales deductions | 43,450 | 41,943 | ||||
| Accrued expenses | 26,890 | 27,427 | ||||
| Accrued income taxes payable | 1,675 | 7 | ||||
| Non-recourse liability related to sale of future royalties, current portion | 4,645 | 3,101 | ||||
| Deferred licensing revenue | 287 | 209 | ||||
| Total current liabilities | 82,003 | 80,742 | ||||
| Deferred licensing revenue, net of current portion | 1,365 | 1,501 | ||||
| Convertible notes, net | 3,310 | 4,165 | ||||
| Non-recourse liability related to sale of future royalties, long term | 25,555 | 27,289 | ||||
| Other non-current liabilities | 3,936 | 4,002 | ||||
| Derivative liabilities | 23 | 114 | ||||
| Total liabilities | 116,192 | 117,813 | ||||
| Total stockholders' equity | 206,064 | 191,755 | ||||
| Total liabilities and stockholders' equity | $ | 322,256 | $ | 309,568 | ||
| Consolidated Statements of Operations | ||||||||
| (in thousands, except share and per share data) | ||||||||
| Three Months Ended | ||||||||
| 2017 | 2016 | |||||||
| (unaudited) | ||||||||
| Revenue | ||||||||
| Net product sales | $ | 56,369 | $ | 43,025 | ||||
| Royalty revenue | 1,149 | 1,119 | ||||||
| Licensing revenue | 58 | 50 | ||||||
| Total revenue | 57,576 | 44,194 | ||||||
| Costs and expenses | ||||||||
| Cost of product sales | 2,949 | 2,035 | ||||||
| Research and development | 9,601 | 10,562 | ||||||
| Selling, general and administrative | 28,238 | 25,160 | ||||||
| Total costs and expenses | 40,788 | 37,757 | ||||||
| Operating income | 16,788 | 6,437 | ||||||
| Other income (expense) | ||||||||
| Interest income | 531 | 327 | ||||||
| Interest expense | (90 | ) | (179 | ) | ||||
| Interest expense-nonrecourse | ||||||||
| liability related to sale of future royalties | (959 | ) | (1,279 | ) | ||||
| Changes in fair value of derivative liabilities | 54 | 101 | ||||||
| Loss on extinguishment of debt | (101 | ) | (382 | ) | ||||
| Total other expense | (565 | ) | (1,412 | ) | ||||
| Earnings before income taxes | 16,223 | 5,025 | ||||||
| Income tax expense | 5,926 | 200 | ||||||
| Net income | $ | 10,297 | $ | 4,825 | ||||
| Income per common share: | ||||||||
| Basic | $ | 0.21 | $ | 0.10 | ||||
| Diluted | $ | 0.19 | $ | 0.08 | ||||
| Weighted-average number of common shares outstanding: | ||||||||
| Basic | 50,158,634 | 49,240,099 | ||||||
| Diluted | 52,764,442 | 51,152,072 | ||||||
CONTACTS:Jack A. Khattar , President and CEOGregory S. Patrick , Vice President and CFOSupernus Pharmaceuticals, Inc. Tel: (301) 838-2591 or INVESTOR CONTACT:Peter Vozzo Westwicke Partners Office: (443) 213-0505 Mobile: (443) 377-4767 Email: peter.vozzo@westwicke.com
News Provided by Acquire Media